SK hires new head of vaccine R&D, clinical development
Plus Sutro’s CMO leaves and updates from Shoreline, Opthea and Aurinia
Korean biotech SK bioscience Co. Ltd. (KSE:302440) consolidated its U.S. corporate entity with the hiring of Harry Kleanthous as EVP of vaccine R&D strategy and external innovation, and Sally Choe as head of global clinical development and regulatory affairs. Kleanthous was senior program officer in global health at the Bill & Melinda Gates Foundation, VP research at Acambis plc, and head of research for North America at Sanofi (Euronext:SAN; NASDAQ:SNY). Choe joins SK from FDA, where she was super office director of the agency’s Office of Generic Drugs.
CMO Arturo Molina will leave Sutro Biopharma Inc. (NASDAQ:STRO) on Nov. 4 to pursue other opportunities, leaving CEO Bill Newell to oversee all clinical activities. Sutro is developing site-specific antibody-drug conjugates for cancers. ...